Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2

Yang Li¹, Dan Wang², Hui Ren³ & Wei Feng¹

1 Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchun, China
2 Department of Breast Surgery, The Second Hospital of Jilin University, Changchun, China
3 Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun, China

Abstract

Background: As a classic oral drug used in diabetic patients, metformin has exhibited an anticancer role in many types of cancers in recent years. Here, we aimed to investigate the role of metformin in the growth of breast cancer and its novel targets.

Methods: A cell viability assay was utilized to examine the inhibitory effect of metformin on proliferation of breast cancer cells. Western blotting and RT-PCR assays were used to detect the regulation of metformin on the expression of oncogenic HMGA2. The luciferase reporter vector of HMGA2 promoter was constructed. A luciferase reporter gene assay was performed to analyze the effect of metformin on HMGA2 promoter activity in breast cancer cells. Chromatin immunoprecipitation (ChIP) assay was performed to show the binding of Sp1 to HMGA2 promoter in breast cancer cells with or without metformin treatment. The function of metformin-regulated HMGA2 in breast cancer growth was tested using a cell viability assay.

Results: Cell proliferation was obviously inhibited in breast cancer cells treated with different concentrations of metformin. The level of mRNA and protein of HMGA2 was significantly reduced by metformin in the cells. Mechanistically, metformin was able to inactivate the HMGA2 promoter through downregulating transcription factor Sp1 in the cells. In terms of function, treatment with metformin suppressed the proliferation of breast cancer cells and overexpressed HMGA2 reversed the inhibition of cell proliferation mediated by metformin.

Conclusion: Metformin resists the growth of breast cancer through targeting Sp1/HMGA2 signal.

Introduction

Breast cancer is predominantly a malignant tumor in women, with high mortality rates worldwide.¹ Serving as an oral hypoglycemic drug, metformin is used in the treatment of diabetes through AMPK signaling pathway.² A previous investigation revealed a low incidence of cancer in diabetic patients treated with metformin.³ An increasing number of studies display the relationship among metformin treatment and cancer incidence or patient survival.³–⁶ Metformin is able to inactivate STAT3 and NF-κB to suppress IL-6-induced breast cancer progression.⁷ Some researchers have observed that metformin can reduce the development of tumor and prolong the survival of patients with T2DM and different cancers, such as prostate cancer, lung cancer, colon cancer or breast cancer.⁸–¹⁰ In certain types of cancer including melanoma, ovarian, prostate, lung, colon or breast cancers, metformin and phenformin have been shown to prevent tumor progression.¹⁰–¹⁴ Metformin together with phenformin also play roles in resisting the development of colon cancer through promoting AMPK and ROS production and inhibiting glycolysis.¹⁵–¹⁷ However, the underlying mechanism of metformin in cancer therapy needs to be further investigated.

As an architectural transcription factor, high-mobility group AT-hook 2 (HMGA2) binds to the AT-rich regions in DNA through its three basic DNA-binding domains...
called “AT-hooks.” By changing chromatin structure, HMGA2 can regulate transcription to affect the expression of many mammalian genes. High HMGA2 is frequently found in tumor tissues but rarely in normal tissues. Overexpressed HMGA2 is closely associated with poor survival of breast, colorectal or lung cancer patients. The evidence proves that oncogenic HMGA2 participates in DNA damage repair, stem cell self-renewal, or tumor growth. HMGA2 is considered to promote tumor development in part through its target genes. For instance, it has been reported that HMGA2 counteracted the transcription repressor p120E4F to induce cyclin A expression, resulting in cell cycle progression. Human telomerase reverse transcriptase (hTERT) can be activated by HMGA2, holding back the telomere shortening in cancer cells. In addition, several studies report that HMGA2 was able to directly activate some pro-metastatic genes, CXCR4, SNAIL or SLUG. Much attention has been focused on the regulatory cascades of HMGA2 expression during cancer progression. It has been shown to be activated by Wnt/β-catenin signaling and repressed by the ZBRK1/BRCA1/ChIP pathway. Yet, whether HMGA2 is involved in metformin-associated breast cancer growth inhibition remains unclear.

In our study, we aimed to clarify the role of HMGA2 in metformin-inhibited breast cancer and its underlying regulatory mechanism. Metformin is able to effectively stifle breast cancer growth in vitro. For the mechanism investigation, metformin inactivates oncogenic HMGA2 transcription through reducing transcription factor Sp1, leading to breast cancer growth inhibition. Our findings might provide another option for clinical breast cancer therapy.

Methods

Cell lines

Breast cancer cell line MCF-7 was grown in RPMI Medium 1640 (Gibco, USA) containing 10% fetal calf serum (FCS, Gibco). Another breast cancer cell line BT-474 was grown in DMEM medium (Gibco), 10% FCS, 100 U/mL penicillin, and 100 μg/mL streptomycin in humidified 5% CO₂ at 37°C.

Cell viability assay

MTT assay was applied to analyze the proliferation ability of breast cancer MCF-7 and BT-474 cells. Breast cancer cells (3000 cells/well) were plated on 96-well plates with at least three replicates and then incubated for 10 hours to form confluent monolayers. After the cells were treated with metformin, 10 μL MTT (5 mg/mL) was added into each well and the absorbance values were evaluated at OD490nm using the absorbance reader.

RNA extraction and PCR

TRIzol reagent was used to extract total RNA from breast cancer MCF-7 or BT-474 cells and 1 μg RNA was reversely transcribed into cDNA for every sample. The mRNA levels of HMGA2 and GAPDH were detected through RT-PCR assay by following the standard protocol. It should be noted that GAPDH served as the internal control for HMGA2 detection.

Western blot analysis

Post-treatment with different doses of metformin, total protein of MCF-7 and BT-474 cells were extracted by using RIPA lysis buffer. The same amount of total protein for each sample was running in SDS-PAGE gel. The primary antibodies including anti-HMGA2 and anti-β-actin were purchased from GeneTex Inc. (Irvine, USA) and Proteintech (Chicago, USA). The secondary antibodies including goat anti-rabbit (Abcam, USA) or anti-mouse antibody (Abcam) were incubated with western blots and the membrane was then visualized by ECL (Millipore). Image J software was used to quantify the intensity in western blotting analysis.

Luciferase reporter gene assay

MCF-7 cells (1 × 10⁵ cells/well) were seeded into 24-well plates with ~70% confluence with at least three repeats for each experiment and then the cotransfection of pGL3-HMGA2, pRL-TK (Promega, USA) and/or metformin treatment (40 mM or 80 mM) were performed. pRL-TK was applied for internal normalization. The cells were collected for the luciferase activity analysis 48 hours later. Luciferase activity was determined using Dual-Luciferase Reporter Gene Assay System (Promega) following the manufacturer’s instructions.

Chromatin immunoprecipitation (ChIP) analysis

EpiQuik chromatin immunoprecipitation kit from Epigentek Group Inc. (Brooklyn, NY) was used in chromatin immunoprecipitation (ChIP) assay by following the manufacturer’s instructions. The protein-DNA complexes were immunoprecipitated with anti-Sp1 or normal rabbit IgG as a negative control antibody. DNA from the above samples was then subjected to PCR assay.
Statistical analysis

Each experiment was performed in triplicate. Statistical significance was evaluated by comparing (± SD) using a Student’s t-test. Nonsignificant difference was marked with ns. Criterion for statistically significant differences were as follows: ***P < 0.001; **P < 0.01; *P < 0.05.

Results

Metformin restraints the proliferation of breast cancer MCF-7 and BT-474 cells

As an oral drug controlling blood glucose in diabetes patients, metformin exerts an antiproliferative effect in multiple cancers including prostate cancer, lung cancer, colon cancer or breast cancer.8,9 However, the function of metformin in preventing breast cancer growth and molecular regulatory mechanism is unclear and needs further clarification. We subsequently performed a cell viability analysis using breast cancer MCF-7 and BT-474 cell lines with or without the administration of metformin. Treatment with increased concentrations of metformin significantly reduced the cell viability of breast cancer (Fig 1a,b). These data indicate that metformin is capable of effectively preventing the proliferation of breast cancer cells.

Metformin inhibits oncogenic HMGA2 in breast cancer

HMGA2, an architectural transcription factor, is abundant in tumor cells and its high expression is related to poor survival rates in many types of cancers including breast cancer, colorectal cancer or lung cancer.18–22 Yet, the role of HMGA2 in metformin-mediated breast cancer inhibition is as yet undetermined. Here, we focus on whether HMGA2 takes part in metformin-depressed breast cancer. After breast cancer MCF-7 and BT-474 cells were treated with an increased dose of metformin, the mRNA and protein level of HMGA2 was evaluated through western blotting and RT-PCR assays. Compared to the control group, HMGA2 was obviously decreased by metformin at the protein level in MCF-7 cell line (Fig 2a). Furthermore, we wanted to investigate whether metformin could modulate the HMGA2 transcription in the cells. We observed that the mRNA level of HMGA2 was markedly decreased by metformin in breast cancer cells (Fig 2b). We further confirmed the above data in another breast cancer cell line BT-474 (Fig 2c,d). Thus, we found that HMGA2 could be reduced by metformin in breast cancer.

Metformin targets transcription factor Sp1 to control HMGA2 transcription

Taking a step further, we then attempted to clarify how metformin regulates HMGA2 in breast cancer. According to the protocol used in a previous study,34 we cloned the core promoter region into pGL3-basic plasmid. We then analyzed whether metformin could regulate the promoter activities of HMGA2 in breast cancer cells. Our data showed that metformin was able to significantly decrease the luciferase activities of pGL3-HMGA2 promoter in MCF-7 and BT-474 cells (Fig 3a,b). As shown in a previous investigation34 and the prediction using the online bioinformatics tool JASPAR database (http://jaspar.genouest.org), transcription factors Sp1 had binding sites in the core promoter region of HMGA2. Accordingly, we tested whether metformin affected the binding of Sp1 to HMGA2 promoter through ChIP-PCR and ChIP-quantitative real-time PCR assay. Our data showed that the binding of Sp1 to HMGA2 promoter was abrogated by metformin in breast cancer cells (Fig 3c,d). In summary, we concluded that metformin could control HMGA2 transcription through targeting Sp1 in breast cancer.

Figure 1 Metformin restrained the proliferation of breast cancer MCF-7 and BT-474 cells. (a, b) The effect of metformin (Met) treatment on the proliferation of MCF-7 and BT-474 cell lines was examined by MTT assay. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant. (a) MCF-7 (i) Met 0 mM, (ii) Met 40 mM and (iii) Met 80 mM. (b) BT-474 (i) Met 0 mM, (ii) Met 40 mM and (iii) Met 80 mM.
HMGA2 is a mediator in metformin-alleviated breast cancer

Based on the finding that metformin regulated HMGA2 in breast cancer cells, we finally analyzed the function of HMGA2 in metformin-inhibited proliferation of breast cancer cells. First, we evaluated the level of HMGA2 in MCF-7 or BT-474 cells treated with metformin and/or HMGA2 transfection (Fig 4a,c). For the administration of 80 mM metformin, the proliferation of MCF-7 or BT-474 cells was obviously reduced. Moreover, HMGA2 overexpression could reverse the decrease in cell proliferation mediated by metformin (Fig 4b,d). Collectively, we concluded that metformin could alleviate breast cancer through targeting HMGA2.

Discussion

Serving as an oral hypoglycemic drug, metformin is widely applied in clinical therapy. Metformin functions in diabetes treatment through AMPK signaling pathway.2 It has been reported that diabetic patients with metformin treatment had a low incidence of cancer.3 There exists a close correlation among metformin treatment and cancer incidence or patient survival.4–6 For the molecular mechanism of metformin in cancer treatment, it has been reported to inactivate STAT3 or NF-κB, preventing IL-6-induced breast cancer progression.7 In prostate cancer, lung cancer, colon cancer or breast cancer patients with T2DM, metformin has been shown to reduce the development of tumor and
prolong the survival.8,9 Metformin together with phenformin also resists the development of colon cancer through promoting AMPK and ROS production and inhibiting glycolysis.15–17 In our study, we were interested in ascertaining the novel targets of metformin in cancer, especially in breast cancer.

First, we tried to evaluate the function of metformin in the development of breast cancer. An increased dose of metformin was able to markedly depress cell viability in breast cancer and confirms that metformin has the ability of suppressing the growth of breast cancer. As an oncogenic architectural transcription factor, HMGA2 can interact with the AT-rich regions of DNA via its “AT-hooks” domain.18 High HMGA2 is frequently observed in tumor tissues but nearly disappears in normal tissues.18,19 HMGA2 augmentation is closely correlated with poor survival of breast, colorectal or lung cancer patients.20–22 The evidence proves that oncogenic HMGA2 participates in DNA damage repair, stem cell self-renewal, or tumor growth.23–26 HMGA2 is considered to promote tumor development in part through its target genes.

In this study, we were curious to ascertain the function of HMGA2 in metformin-inhibited growth of breast cancer cells. The data showed that oncogenic HMGA2 could be sharply downregulated by metformin at the promoter, mRNA and protein level. We then attempted to clarify how metformin modulated oncogenic HMGA2. A previous study34 and website prediction demonstrated that transcription factor Sp1 might activate HMGA2 transcription, implying that Sp1 could take part in metformin-downregulated HMGA2 in breast cancer cells. The results from the ChIP assay proved that the binding of Sp1 to HMGA2 promoter could be reduced by treatment with metformin. Finally, our data revealed that HMGA2 was involved in metformin-suppressed breast cancer.

---

**Figure 3** Metformin targeted transcription factor Sp1 to control HMGA2 transcription. (a, b) Effect of metformin (Met) on HMGA2 transcription in MCF-7 and BT-474 cell lines was analyzed by luciferase reporter gene assay. ***P < 0.001; **P < 0.01. (c, d) The binding of Sp1 to HMGA2 promoter with or without the addition of metformin was tested by ChIP and PCR or quantitative realtime PCR assays.
In summary, the findings from our study present a novel mechanism for ameliorating breast cancer under metformin treatment. Metformin can effectively stifle breast cancer growth. As a novel target, HMGA2 is obviously decreased in metformin-resisted breast cancer. Metformin regulates transcription factor Sp1 to reduce HMGA2 activation, leading to the inhibition of breast cancer growth. Our finding emphasizes that metformin should be used in breast cancer therapy.

Acknowledgments

This study was supported by the Department of Science and Technology of Jilin Province (No. 20180101136JC), the Department of Finance of Jilin Province (No. 2018SCZ030), the Excellent Talents Training Plan China-Japan Union Hospital of Jilin University (No. YXZN-201803), Medical and Health Project of Jilin Province (No. 20190304047YY) and International cooperation projects of Jilin Province (No. 20160414047GH).

Disclosure

No authors report any conflict of interest.

References

1 Vargo-Gogola T, Rosen JM. Modelling breast cancer: One size does not fit all. Nat Rev Cancer 2007; 7: 659–72.
2 Luengo A, Sullivan LB, Heiden MG. Understanding the complex-I-ty of metformin action: Limiting mitochondrial respiration to improve cancer therapy. BMC Biol 2014; 12: 82.
3 Clarke PM, Gray AM, Briggs A et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868–77.
4 Ioannou GN, Boyko EJ. Metformin and colorectal cancer risk in diabetic patients. Diabetes Care 2011; 34: 2336–7.
Metformin inhibits breast cancer

Y. Li et al.

5 Chen CB, Eskin M, Euirch DT, Majumdar SR, Johnson JA. Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: A systematic review and meta-analysis. BMC Cancer 2018; 18: 65.

6 Yu H, Zhong X, Gao P et al. The potential effect of metformin on cancer: An umbrella review. Front Endocrinol (Lausanne) 2019; 10: 617.

7 Esparza-Lopez J, Alvarado-Munoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, de Jesus Ibarra-Sanchez M. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-kappaB pathways. BMC Cancer 2019; 19: 728.

8 Meng F, Song L, Wang W. Metformin improves overall survival of colorectal cancer patients with diabetes: A meta-analysis. J Diabetes Res 2017; 2017: 5063239.

9 Tian S, Lei HB, Liu YL, Chen Y, Dong WG. The association between metformin use and colorectal cancer survival among patients with diabetes mellitus: An updated meta-analysis. Chronic Dis Transl Med 2017; 3: 169–75.

10 Queiroz EA, Puukila S, Eichler R et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLOS One 2014; 9: e89207.

11 Qu C, Zhang W, Zheng G, Zhang Z, Yin J, He Z. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol Cell Biochem 2014; 386: 63–71.

12 Azvolinsky A. Repurposing to fight cancer: The metformin-prostate cancer connection. J Natl Cancer Inst 2014; 106: dju030.

13 Lea MA, Pourat J, Patel R, desBordes C. Growth inhibition of colon cancer cells by compounds affecting AMPK activity. World J Gastrointest Oncol 2014; 6: 244–52.

14 Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Golliwe WH. Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol 2011; 121: 492–8.

15 Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008; 1: 369–75.

16 Mogavero A, Maiorana MV, Zanutto S et al. Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Sci Rep 2017; 7: 15992.

17 Park JH, Kim YH, Park EH et al. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. Cancer Sci 2019; 110: 2834–45.

18 Sgarra R, Rustighi A, Tessari MA et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004; 574: 1–8.

19 Fedele M, Visone R, De Martino I et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006; 9: 459–71.

20 Langelotz C, Schmid P, Jakob C et al. Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003; 88: 1406–10.

21 Wang X, Liu X, Li AY et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 2011; 17: 2570–80.

22 Sarhadi VK, Wikman H, Salmenkivi K et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006; 209: 206–12.

23 Summer H, Li O, Bao Q et al. HMGA2 exhibits drp1/AMPK site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res 2009; 37: 4371–84.

24 Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 2008; 135: 227–39.

25 Peng Y, Laser J, Shi G et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008; 6: 663–73.

26 Shell S, Park SM, Radjabi AR et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007; 104: 11400–5.

27 Tessari MA, Gostissa M, Altamura S et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003; 23: 9104–16.

28 Li AY, Lin HH, Kuo CY et al. High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol 2011; 31: 2605–17.

29 Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z, You T. HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression. Cancer Lett 2014; 355: 130–40.

30 Thuault S, Tan EI, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 2008; 283: 33437–46.

31 Yun J, Frankenberg CA, Kuo WL et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 2011; 30: 4500–14.

32 Wend P, Runke S, Wend K et al. WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med 2013; 5: 264–79.

33 Ahmed KM, Tsai CY, Lee WH. Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis. J Biol Chem 2010; 285: 4464–71.

34 Chau K, Arlotta P, Patel UA, Crane-Robinson C, Manfioletti G, Ono SJ. A novel downstream positive regulatory element mediating transcription of the human high mobility group (HMG) I-C gene. FEBS Lett 1999; 457: 429–36.